Novartis plans to buy The Medicines Company for USD 9.7 Billion to gain access to a heart drug inclisiran, almost ready to get into the market. Under the terms of the deal, Novartis will pay USD 85 per share to the Medicines Company, a cholesterol drug developer, making the deal up to USD 9.7 Billion. The whole...
Find MoreMead Johnson Acquired By Reckitt Benckiser for $16.6 Billion Mead Johnson Nutrition Company (MJN), the manufacturer of infant formula and nutritional supplements, has agreed to be acquired by Britain's Reckitt Benckiser Group plc in a deal that values the former's equity at $16.6 billion. Mead Johnson shareholders w...
Find MoreAMRI enters alliance with Bruker Daltonics and HighRes Biosolutions AMRI has entered an alliance with Bruker Daltonics and HighRes Biosolutions to develop new applications for using high throughput mass spectrometry (MS) for drug discovery. AMRI has acquired the new MALDI PharmaPulse system from Bruker Daltonics and...
Find MoreLive Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!